Tags » Novartis

Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursday, cancer drug maker Allogene Therapeutics pulled off the biggest public offering… 319 more words


Perrigo looks for stability in its third CEO since March.

Perrigo, the leading maker of private-label over-the-counter drugs, is once again testing investors patience with a surprise management change. But that unsettling news also creates a future opportunity. 198 more words

Breakthrough leukemia treatment backfires in 'exceptionally rare' case

A highly unusual death has exposed a weak spot in a groundbreaking cancer treatment: One rogue cell, genetically altered by the therapy, can spiral out of control in a patient and cause a fatal relapse. 807 more words


An Extensive Report On DNA Vaccines Market 2018 Global Analysis By Key Players – Sanofi Aventis, Pfizer, Novartis, Merck, GlaxoSmithKline, ABL, Immunologicals, Xenetic Biosciences, QED Biosciences

DNA Vaccines Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. 864 more words

Once Daily: September 26, 2018

Today’s Essential Reading:

FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases ( 73 more words


Jordin Sparks teams up with Novartis and SCDAA

From press release:

Novartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project… 970 more words

Who's Making A Difference?

SLE Market Likely To Reach A Valuation Of Around USD 3.08 Billion By 2025 | Key Industry participants GlaxoSmithKline, Roche

The global Systemic Lupus Erythematosus Market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. 534 more words